GA
FLXN

Gagnon Advisors’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Gagnon Advisors’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-431,306
Closed -$3.39M – 27
2020
Q1 		$3.39M Hold
431,306
– – 3.17% 14
2019
Q4 		$8.93M Hold
431,306
– – 5.01% 6
2019
Q3 		$5.91M Buy
431,306
+29,658
+7% +$352K 3.67% 14
2019
Q2 		$4.94M Hold
401,648
– – 2.82% 17
2019
Q1 		$5.01M Buy
401,648
+189,860
+90% +$2.54M 2.87% 19
2018
Q4 		$2.4M Sell
211,788
-13,274
-6% -$208K 1.68% 23
2018
Q3 		$4.21M Hold
225,062
– – 2.52% 18
2018
Q2 		$5.82M Buy
225,062
+32,624
+17% +$847K 3.68% 13
2018
Q1 		$4.31M Hold
192,438
– – 3.21% 16
2017
Q4 		$4.82M Buy
192,438
+83,940
+77% +$2.06M 3.53% 15
2017
Q3 		$2.62M Buy
+108,498
New +$2.55M 1.99% 23

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Gagnon Advisors's FLXN Position: Q2 2020 in Review

Gagnon Advisors sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2020, closing a stake of 431,306 shares — an estimated $3.39M sold.

Gagnon Advisors first reported a position in FLXN in Q3 2017 and held it in 11 quarters. The position peaked at $8.93M in Q4 2019. 125 funds tracked by Wall St. Rank hold FLXN as of Q2 2020.

  • Gagnon Advisors reported no remaining Flexion Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Gagnon Advisors sold 431,306 Flexion Therapeutics, Inc. shares in Q2 2020, an estimated $3.39M.
  • Gagnon Advisors first reported a position in Flexion Therapeutics, Inc. in Q3 2017 and held it in 11 quarters.
  • Gagnon Advisors's Flexion Therapeutics, Inc. position peaked at $8.93M in Q4 2019.
  • 125 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2020.

Based on Gagnon Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.